Product Reports Resources Pricing Login Book a demo

Spero Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2017

Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections

Valuation $14M
Revenue $60M
EBITDA $8.0M

Talent graph

Spero Therapeutics's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 4 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

13 investors on Spero Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Atlas Peak Capital
Atlas Venture
Series A 5 investors entered at this stage
Partners Innovation Fund
Lundbeckfonden Ventures
SR One
The Kraft Group
Lundbeckfonden
Series B+ 6 investors entered at this stage
Massachusetts General Hospital
Rock Springs Capital
Osage University Partners
GV
RA Capital Management
Harvard Medical School

Global footprint

Where Spero Therapeutics has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

What the market is saying about Spero Therapeutics

An AI-synthesized read of the highest-engagement posts about Spero Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Spero Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.